This page shows the latest sotagliflozin news and features for those working in and with pharma, biotech and healthcare.
ESC in the build-up to its planned new drug application for sotagliflozin in heart failure later this year. ... Sotagliflozin is an inhibitor of glucose regulation proteins SGLT1 and SGLT2 (sodium-glucose co-transporter types 1 and 2).
It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista (sotagliflozin) for this use in December, once again despite an earlier approval in Europe.
Earlier this year the panel was split on whether they should back approval of Lexicon Pharma’s Zynquista (sotagliflozin) as an insulin adjunct in these patients, and the FDA’s subsequent
The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its basal insulin Lantus.
Zynquista (sotagliflozin).
Sanofi has been less fortunate with its US marketing application for Lexicon Pharma-partnered dual SGLT1/SGLT2 inhibitor Zynquista (sotagliflozin) alongside insulin in type 1 diabetes, however, as this was rejected
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...